INCY
Price:
$61.26
Market Cap:
$11.80B
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical tr...[Read more]
Industry
Biotechnology
IPO Date
1993-11-04
Stock Exchange
NASDAQ
Ticker
INCY
According to Incyte Corporation’s latest financial reports and current stock price. The company's current Enterprise Value is 10.85B. This represents a change of 2.37% compared to the average of 10.60B of the last 4 quarters.
The mean historical Enterprise Value of Incyte Corporation over the last ten years is 15.62B. The current 10.85B Enterprise Value has changed 6.85% with respect to the historical average. Over the past ten years (40 quarters), INCY's Enterprise Value was at its highest in in the March 2017 quarter at 25.78B. The Enterprise Value was at its lowest in in the September 2014 quarter at 8.57B.
Average
15.62B
Median
15.95B
Minimum
10.87B
Maximum
19.58B
Discovering the peaks and valleys of Incyte Corporation Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 61.73%
Maximum Annual Enterprise Value = 19.58B
Minimum Annual Increase = -33.20%
Minimum Annual Enterprise Value = 10.87B
Year | Enterprise Value | Change |
---|---|---|
2023 | 10.87B | -27.19% |
2022 | 14.92B | 5.43% |
2021 | 14.16B | -19.06% |
2020 | 17.49B | 2.98% |
2019 | 16.98B | 37.43% |
2018 | 12.36B | -33.20% |
2017 | 18.50B | -1.79% |
2016 | 18.84B | -3.78% |
2015 | 19.58B | 57.12% |
2014 | 12.46B | 61.73% |
The current Enterprise Value of Incyte Corporation (INCY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
13.32B
5-year avg
14.88B
10-year avg
15.62B
Incyte Corporation’s Enterprise Value is less than Alnylam Pharmaceuticals, Inc. (33.42B), less than United Therapeutics Corporation (14.52B), greater than Ultragenyx Pharmaceutical Inc. (5.53B), greater than Apellis Pharmaceuticals, Inc. (5.11B), less than BeiGene, Ltd. (19.49B), less than BioMarin Pharmaceutical Inc. (16.13B), greater than ImmunoGen, Inc. (8.19B), greater than Prometheus Biosciences, Inc. (9.47B), greater than Arrowhead Pharmaceuticals, Inc. (3.15B), greater than Ionis Pharmaceuticals, Inc. (8.54B), greater than Axsome Therapeutics, Inc. (4.35B), less than Sarepta Therapeutics, Inc. (13.28B), greater than ACADIA Pharmaceuticals Inc. (2.55B), greater than Amicus Therapeutics, Inc. (3.69B), greater than Denali Therapeutics Inc. (3.59B), less than argenx SE (31.01B), greater than Harmony Biosciences Holdings, Inc. (1.92B),
Company | Enterprise Value | Market cap |
---|---|---|
33.42B | $31.68B | |
14.52B | $15.38B | |
5.53B | $5.09B | |
5.11B | $5.00B | |
19.49B | $21.01B | |
16.13B | $16.01B | |
8.19B | $8.73B | |
9.47B | $9.56B | |
3.15B | $2.76B | |
8.54B | $6.86B | |
4.35B | $4.47B | |
13.28B | $12.29B | |
2.55B | $2.67B | |
3.69B | $3.46B | |
3.59B | $3.61B | |
31.01B | $32.41B | |
1.92B | $2.02B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Incyte Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Incyte Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Incyte Corporation's Enterprise Value?
What is the highest Enterprise Value for Incyte Corporation (INCY)?
What is the 3-year average Enterprise Value for Incyte Corporation (INCY)?
What is the 5-year average Enterprise Value for Incyte Corporation (INCY)?
How does the current Enterprise Value for Incyte Corporation (INCY) compare to its historical average?